IRIDEX Corporation manufactures therapeutic laser systems and delivery devices for ophthalmologic applications. The company's product portfolio addresses sight-threatening eye diseases including glaucoma, diabetic retinopathy, retinal tears, retinal detachments, and macular holes. Its laser console systems—including the Cyclo G6 for glaucoma treatment and the IQ 532 and IQ 577 platforms for retinal disorders—form the core of its offerings. The company also produces a range of delivery devices such as slit lamp adapters, scanning laser systems, and laser indirect ophthalmoscopes that enable physicians to perform photocoagulation and laser therapy procedures.
Revenue streams derive from the sale of laser consoles, delivery devices, and consumable instrumentation used across the treatment pathway. Additional products include specialized probes such as the MicroPulse P3 for transscleral laser therapy, the G-Probe family for refractory glaucoma treatment, and EndoProbe products for endophotocoagulation procedures.
The company operates with approximately 93 full-time employees and maintains headquarters in Mountain View, California. It distributes products through a direct sales force in the United States and via independent distributors across Europe, the Middle East, Africa, Asia-Pacific, and the Americas. Customer bases include ophthalmologists, research and teaching hospitals, surgical centers, and office clinics, as well as veterinary practices.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.54 | $-0.54 | +8.5% | |
| 2023 | $-0.59 | $-0.59 | -25.5% | |
| 2022 | $-0.47 | $-0.47 | -38.2% | |
| 2021 | $-0.34 | $-0.34 | +46.9% | |
| 2019 | $-0.64 | $-0.64 | +39.0% | |
| 2018 | $-1.05 | $-1.05 | -138.6% | |
| 2017 | $-0.44 | $-0.44 | +61.7% | |
| 2016 | $-1.15 | $-1.15 | -2400.0% | |
| 2015 | $0.05 | $0.05 | -94.8% | |
| 2014 | $0.97 | $1.01 | +340.9% | |
| 2013 | $0.22 | $0.24 | +37.5% | |
| 2012 | $0.16 | $0.16 | — | |
| 2011 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-28 | 2025-03-27 | 0000950170-25-046107 | SEC ↗ |
| 2023-12-30 | 2024-03-29 | 0000950170-24-038650 | SEC ↗ |
| 2022-12-31 | 2023-03-09 | 0000950170-23-007061 | SEC ↗ |
| 2022-01-01 | 2022-03-15 | 0001564590-22-010477 | SEC ↗ |
| 2021-01-02 | 2021-03-23 | 0001564590-21-014859 | SEC ↗ |
| 2019-12-28 | 2020-03-13 | 0001564590-20-010869 | SEC ↗ |
| 2018-12-29 | 2019-03-29 | 0001564590-19-010196 | SEC ↗ |
| 2017-12-30 | 2018-03-14 | 0001564590-18-005593 | SEC ↗ |
| 2016-12-31 | 2017-03-15 | 0001564590-17-004462 | SEC ↗ |
| 2016-01-02 | 2016-03-31 | 0001564590-16-015763 | SEC ↗ |
| 2015-01-03 | 2015-04-02 | 0001564590-15-002365 | SEC ↗ |
| 2013-12-28 | 2014-03-27 | 0001564590-14-001025 | SEC ↗ |
| 2012-12-29 | 2013-03-28 | 0001193125-13-132256 | SEC ↗ |
| 2011-12-31 | 2012-03-30 | 0001193125-12-143973 | SEC ↗ |
| 2011-01-01 | 2011-03-25 | 0001193125-11-076800 | SEC ↗ |
| 2010-01-02 | 2010-03-31 | 0001193125-10-073378 | SEC ↗ |
| 2009-01-03 | 2009-04-01 | 0001193125-09-070788 | SEC ↗ |
| 2007-12-29 | 2008-04-10 | 0000891618-08-000211 | SEC ↗ |
| 2006-12-30 | 2007-03-30 | 0000891618-07-000207 | SEC ↗ |